SCHEMBL6529224

SCHEMBL6529224

COC(=O)[C@H](CC(C)C)Nc1nc(Cl)nc(Oc2ccc(OC)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPR3 P17342 4/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
TAS1R3 Q7RTX0 3/20 0.45
TAS1R1 Q7RTX1 3/20 0.45
PTGS2 P35354 2/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
ELANE P08246 3/20 0.40
ALDH1A1 P00352 1/20 0.39
ANPEP P15144 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6529952 0.82 NPR3 (0.42) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6530303 0.82 VNN1 (0.44) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6529959 0.82 NPR3 (0.42) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL17424044 0.82 NPR3 (0.78) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6529615 0.80 TAS1R3 (0.39) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6529614 0.80 TAS1R3 (0.39) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6528199 0.78 ANPEP (0.43) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6528195 0.78 ANPEP (0.43) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6512165 0.77 NPR3 (0.47) NPR3CYP2C9CYP2C19TAS1R3TAS1R1
SCHEMBL6512169 0.77 NPR3 (0.47) NPR3CYP2C9CYP2C19TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed